Radiation Therapy Target Objectives For Tonsillar Cancer Treated with Unilateral Radiation Therapy - A Replanning Study From TROG 12.01 [0.03%]
单侧放疗咽旁肿瘤的靶区定义及重计划研究(TROG 12.01试验)
Glen Osbourne,Aimee Devlin,Nadia Walsh et al.
Glen Osbourne et al.
Introduction: Unilateral radiotherapy (URT) is an effective treatment strategy in selected patients with lateralized tonsil cancer. However, there is a lack of established planning guidelines for URT treatment leading to ...
Stereotactic body radiotherapy with continued first-line PD-1 inhibitor-based therapy as a resistance-overcoming strategy in oligoprogressive hepatocellular carcinoma: A prospective phase II clinical study [0.03%]
立体定向体放射治疗联合持续一线PD-1抑制剂治疗少数病灶进展的肝细胞癌：一项前瞻性II期临床研究
Shu-Jung Hsu,Yen-Cheng Chao,Si-Wei Wang et al.
Shu-Jung Hsu et al.
Purpose: This prospective phase II trial (NCT06870942) aimed to evaluate whether stereotactic body radiotherapy (SBRT) combined with continued first-line PD-1 inhibitor-based therapy could overcome acquired resistance and...
Stereotactic Body Radiation Therapy With Pembrolizumab in PD-1 Inhibitor Refractory, Recurrent or Metastatic, Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial [0.03%]
立体定向体放射治疗联合派姆单抗治疗PD-1抑制剂耐药的复发或转移性头颈部鳞状细胞癌：一项II期临床试验
Jonathan So,Alexander Droznin,Payal Tiwari et al.
Jonathan So et al.
Purpose: To evaluate the safety, feasibility, and clinical efficacy of stereotactic body radiation therapy (SBRT) combined with pembrolizumab in patients with recurrent or metastatic (R/M) head and neck squamous cell carc...
Hatim Fakir,Gage Redler,Glenn S Bauman et al.
Hatim Fakir et al.
Patients with polymetastatic cancer have traditionally been treated with systemic therapies, while radiotherapy has played a mainly supportive role, typically using simple, non-conformal techniques for palliation of the most symptomatic sit...
Gaining New Ground: The Evolving Role of Radiation Therapy in Esophageal Cancer [0.03%]
放射治疗在食管癌中的作用：新的进展及角色转换
Eric D Miller,Jonathan B Ashman,Aisling Barry et al.
Eric D Miller et al.
Radiation therapy (RT) in the management of esophageal cancer is evolving. Advances in systemic therapy have altered the role of RT as preoperative therapy in patients with resectable esophageal adenocarcinoma. However, RT continues to play...
Phase II Prospective Trial of Personalized Radiotherapy Fractionation in Human Papillomavirus Positive Oropharyngeal Cancer [0.03%]
一项针对人类乳头瘤病毒阳性口腔咽癌的个性化放疗分割二期前瞻性试验
Jimmy Caudell,Michelle Echevarria,George Yang et al.
Jimmy Caudell et al.
Purpose: We previously developed a model of pre-treatment growth and on-treatment response dynamics, the proliferation saturation index (PSI) model, which derives the proliferating and radiosensitive proportion of a tumor...
Integrated Radiotherapy with Immune-Chemotherapy for Unresectable Biliary Tract Cancer: An Exploratory Pilot Study [0.03%]
不可切除胆道癌放疗联合免疫化疗的探索性序贯治疗研究
Zhaohan Zhang,Han Li,Yuxuan Wang et al.
Zhaohan Zhang et al.
Background: Although immunotherapy-chemotherapy represents the latest first-line standard for unresectable biliary tract cancer (BTC), the survival outcome remains unsatisfactory. Radiotherapy exerts synergistic effects w...
Toxicity and Treatment Completion of Neoadjuvant FOLFOXIRI and Chemoradiotherapy in patients with High-Risk Locally Advanced Rectal Cancer: A Secondary Outcome Analysis of the MEND-IT Trial [0.03%]
新辅助FOLFOXIRI联合放疗治疗高危局部晚期直肠癌的毒性及治疗完成情况：MEND-IT试验的次要结果分析
E Banken,K van den Berg,I E G van Hellemond et al.
E Banken et al.
Introduction: Total neoadjuvant therapy (TNT) is a promising strategy to improve tumor response and oncological outcomes in locally advanced rectal cancer (LARC) patients, particularly in those with high-risk tumor charac...
Laurent Kelleter,Semi Harrabi,Pamela Ochoa-Parra et al.
Laurent Kelleter et al.
Purpose: Ion-beam radiotherapy offers steep dose gradients and high biological effectiveness required for the treatment of complex cancer cases. While the vast majority of ion-beam therapy centers today use protons and ca...
Real-World Endpoints in Stereotactic Body Radiation Therapy Trials for Oligoprogression: Beyond Progression-Free Survival and Overall Survival [0.03%]
立体定向体放射治疗寡进展临床试验的现实终点：超越无进展生存期和总生存期
Steven David,Michelle White,Shankar Siva et al.
Steven David et al.